Polynovo Earnings Call Highlights Strong Growth Momentum

Polynovo Limited ((AU:PNV)) has held its Q2 earnings call. Read on for the main highlights of the call.

Polynovo’s latest earnings call struck a confident tone, with management emphasizing robust double‑digit revenue growth, accelerating MTX adoption, stronger cash generation, and a deepening clinical evidence base. Short‑term headwinds from manufacturing timing, FX and a lab fire were framed as largely one‑off effects, with expectations for margin and cash flow to strengthen into the second half.

Broad‑Based Surge in Group Revenue

Group NovoSorb product sales climbed to $68.2 million, a 26% year‑on‑year increase that adds $14.1 million of additional revenue and demonstrates sustained demand for the portfolio. Management highlighted that this growth provides solid momentum heading into the second half, despite some lumpiness from burn‑related case volumes.

U.S. Engine Delivers Profitable Expansion

U.S. revenue reached $51.7 million, up 25.3% year‑on‑year, underscoring the U.S. franchise as the key earnings engine for Polynovo. The company added 95 new hospital accounts to surpass 800 in total, and the U.S. business is already profitable and throwing off strong cash flows to fund further expansion.

International Markets Gain Strategic Weight

Rest‑of‑world revenue rose to $16.5 million, up 28.3% and now about 24% of global sales, signaling a more diversified earnings base. Notable standouts included Australia up 52%, Canada up 50.8%, Germany up 28.3%, Turkey up 91.3% and India up 49.1%, albeit from a smaller and more complex tender‑driven base.

MTX Adoption Accelerates Beyond Burns

NovoSorb MTX delivered around $6.0–6.2 million of sales, representing roughly 193–195% growth and one of the fastest‑growing parts of the portfolio. MTX is now used in more than 240 U.S. accounts and is steadily expanding into indications beyond burns, broadening the addressable market and deepening usage per account.

Contract Channels Deepen U.S. Coverage

Contracted U.S. channels showed strong traction, with group purchasing organization sales up 37.8%, IDM sales up 34.1% and federal account sales surging 87.2%. These contracted channels now account for 39.9% of U.S. revenue, improving visibility, pricing discipline and access to larger institutional customers.

Cash Generation and Balance Sheet Strengthen

Polynovo ended the half with $29.2 million in cash and a sharp turnaround in operating cash flow to a $9.0 million inflow from a $12.5 million outflow previously. Debtor days in the U.S. were cut from more than 90 to 56, tightening working capital and giving the company more financial flexibility without needing external capital.

Underlying Profitability Tracks Higher

Adjusted EBITDA rose 82% year‑on‑year to $4.7 million after stripping out significant items such as the R&D lab fire and unrealized FX movements. Management stressed that, when timing‑related issues are excluded, underlying EBITDA is trending positively and should benefit as capacity ramps and one‑off costs roll off.

New Facility Unlocks Major Capacity Upside

The new manufacturing facility has completed construction and is in validation, with management estimating it can deliver roughly five times prior capacity and support a broader SKU mix. Around $2.2 million of remaining CapEx is slated for the second half, after which the plant should underpin scalable growth and supply resilience.

Regulatory Progress and Expanding Clinical Evidence

The PMA submission for an on‑label indication in full‑thickness burns is in its final stages and targeted for year‑end, supported by the BARDA partnership. Polynovo now cites 348 peer‑reviewed real‑world studies, including 65 supporting outpatient use and five in diabetic limb salvage, with pivotal RCT data expected within six to twelve months.

Outpatient Strategy Positions Optional Upside

To navigate shifting U.S. outpatient reimbursement, Polynovo is advancing its SynPath bilayer brand under an existing code while expecting a monolayer matrix code later this year and preparing outpatient‑specific sizes and inventory. Management framed outpatient revenue as incremental upside to existing internal forecasts, rather than a dependency for near‑term growth.

Leadership Refresh and Talent Build‑Out

The leadership bench has been strengthened with a new CEO, Bruce Peatey, a new Company Secretary and General Counsel, and the promotion of Allison Myers to Chief Quality and Regulatory Affairs Officer. The company is actively hiring a Chief Scientific Officer, a Market Access Director and a Senior Product Manager in the U.S. to drive scientific strategy, reimbursement and commercial execution.

Temporary Output Slowdown Weighs on Margins

Management deliberately slowed manufacturing in the half to complete validation work and prepare for a PMA‑linked FDA audit, creating an unfavorable manufacturing variance of about $3.6–3.7 million. This pulled reported gross margin down to 88.8%, but the team expects margins to exceed 90% for the full year once production normalizes.

Lab Fire and FX Movements Cloud Headline Numbers

An R&D lab fire triggered a $4.4 million asset write‑off, largely offset by a $4.6 million interim insurance claim, though it did cause operational disruption and will require a minor rebuild. Meanwhile, a stronger Australian dollar produced an unrealized FX loss of $0.76 million versus a prior‑period gain, muting reported profit momentum despite solid operating performance.

BARDA Trial Wind‑Down and Market Variability

As the pivotal BARDA burns trial nears completion, associated R&D revenue and trial costs have both declined, reducing BARDA‑related contributions this period. Management also pointed to seasonal softness and fewer large burn cases, particularly in November, underscoring the inherent quarter‑to‑quarter volatility in burn‑driven revenue.

Scaling Costs and India’s Slower Tender Ramp

Employee expenses rose 12.2% year‑on‑year, including about $0.7 million in restructuring costs, as headcount climbed from 254 to roughly 302 to support growth. In India, complex tender processes have slowed commercialization relative to earlier expectations, even though recent growth is improving and is expected to compound over time.

Forward‑Looking Outlook and Key Milestones

While Polynovo declined to issue formal earnings guidance, management outlined clear directional markers: continuing double‑digit NovoSorb growth, MTX penetration across more than 240 U.S. accounts, and U.S. hospital coverage above 800 supported by more than 80 sales reps. They expect gross margins to move above 90% next year as a one‑off manufacturing variance rolls off, cash generation to remain positive, the Port Melbourne plant to fire up from July, and major clinical and regulatory milestones—including PMA submission and upcoming RCT data—to support further market expansion, with outpatient contributions treated as upside.

Polynovo’s earnings call painted the picture of a high‑growth medtech business transitioning from build‑out to scale, with U.S. profitability, rising international contributions and strong MTX momentum anchoring the story. Short‑term noise from FX, one‑offs and burn‑volume variability remains, but management’s focus on capacity, evidence and outpatient access suggests a company positioning for a larger role in global soft‑tissue reconstruction markets.